Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection
David S. Khoury, Timothy E. Schlub, Deborah Cromer, et al.
Emerging infectious diseases (2023) Vol. 29, Iss. 2, pp. 381-388
Open Access | Times Cited: 102

Showing 1-25 of 102 citing articles:

Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis
Deborah Cromer, Megan Steain, Arnold Reynaldi, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 78
Predicting the efficacy of variant-modified COVID-19 vaccine boosters
David S. Khoury, Steffen S. Docken, Kanta Subbarao, et al.
Nature Medicine (2023) Vol. 29, Iss. 3, pp. 574-578
Open Access | Times Cited: 73
Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial
Ghady Haidar, S. Thomas, Paul Loubet, et al.
The Lancet Infectious Diseases (2025)
Closed Access | Times Cited: 1
Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history
Wei Wang, Sabrina Lusvarghi, Rahul Subramanian, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 12, pp. 1745-1758.e7
Open Access | Times Cited: 59
Monoclonal antibody levels and protection from COVID-19
Eva Stadler, Martin Burgess, Timothy E. Schlub, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 31
The immune response to SARS-CoV-2 in people with HIV
Maxine A. Höft, Wendy A. Burgers, Catherine Riou
Cellular and Molecular Immunology (2023) Vol. 21, Iss. 2, pp. 184-196
Open Access | Times Cited: 29
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
David Benkeser, Youyi Fong, Holly Janes, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 26
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
Dean Follmann, Meagan P. O’Brien, Jonathan Fintzi, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 26
Transforming vaccinology
Rino Rappuoli, Galit Alter, Bali Pulendran
Cell (2024) Vol. 187, Iss. 19, pp. 5171-5194
Closed Access | Times Cited: 10
Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination
Carla Martín Pérez, Ruth Aguilar, Alfons Jiménez, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 9
Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial
Margaretha Prins, Geert V.T. Roozen, Cilia R. Pothast, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals
Rebecca Urschel, Saskia Bronder, Verena Klemis, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE
S Kavikondala, Katrin Haeussler, Xuan Wang, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 7, pp. 1419-1438
Open Access | Times Cited: 6
Immune imprinting: The persisting influence of the first antigenic encounter with rapidly evolving viruses
Mariam Maltseva, Alexa Keeshan, Curtis Cooper, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 6
Immune and behavioral correlates of protection against symptomatic post-vaccination SARS-CoV-2 infection
Emilie Goguet, Cara Olsen, William A. Meyer, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines
Yaniv Lustig, Noam Barda, Yael Weiss-Ottolenghi, et al.
Vaccine (2024) Vol. 42, Iss. 22, pp. 126010-126010
Closed Access | Times Cited: 5
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial
Júlia Corominas, Carme Garriga, Antoni Prenafeta, et al.
Vaccine (2025) Vol. 47, pp. 126685-126685
Open Access
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): a prospective cohort study.
Shuo Feng, Sagida Bibi, Parvinder K. Aley, et al.
Journal of Infection (2025) Vol. 90, Iss. 2, pp. 106423-106423
Open Access
In vivo determination of protective antibody thresholds for SARS-CoV-2 variants using mouse models
Peilan Wei, Ruoxi Cai, Lu Zhang, et al.
Emerging Microbes & Infections (2025)
Open Access
Variant-specific antibody correlates of protection against SARS-CoV-2 Omicron symptomatic and overall infections
José Víctor Zambrana, Ian A. Mellis, Abigail Shotwell, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Computational tools and data integration to accelerate vaccine development: challenges, opportunities, and future directions
Lindsey Anderson, Charles Tapley Hoyt, Jeremy Zucker, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Bivalent Coronavirus Disease 2019 Vaccine Antibody Responses to Omicron Variants Suggest That Responses to Divergent Variants Would Be Improved With Matched Vaccine Antigens
Wei Wang, Emilie Goguet, Stephanie Paz, et al.
The Journal of Infectious Diseases (2023) Vol. 228, Iss. 4, pp. 439-443
Open Access | Times Cited: 15
Predicting Vaccine Effectiveness for Hospitalization and Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers
Billy J. Gardner, A. Marm Kilpatrick
Viruses (2024) Vol. 16, Iss. 3, pp. 479-479
Open Access | Times Cited: 4
A spike virosome vaccine induces pan-sarbecovirus antibody responses in mice
Mitch Brinkkemper, Meliawati Poniman, Esther Siteur-van Rijnstra, et al.
iScience (2024) Vol. 27, Iss. 5, pp. 109719-109719
Open Access | Times Cited: 4
Dynamics of anti-SARS-CoV-2 IgG antibody responses following breakthrough infection and the predicted protective efficacy: a longitudinal community-based population study in China
Xiaolong Yan, Xin Zhao, Yin Du, et al.
International Journal of Infectious Diseases (2024) Vol. 145, pp. 107075-107075
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top